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Conclusions: 1) Ang II formation can be measured in the intact human
heart; 21 ACE mediates 90% of Ang I to Ang II conversion across the my-
ocardial circulation.
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phosphodiesterases (POE), we assessed a role for altered cGMp·POE activity
(pmollmln/mg) In the blunted renal ANP response in HF, Isolated glomeruli
and inner medullary collecting duct cells (IMCO) from kidneys of mongrel
dogs 8 days follOWing TIVCC (n = 4) were compared to control animals (n
= 6). Total cGMP-POE actiVity in the presence of 10 I'M calcium (Ca) and
10 JLg/ml calmodulin (CaM) was significantly higher in glomeruli from TIVCC
(657 ±81 vs. control 361 ± 31, P <:: 0.05) but not in 1MCD (2693± 794vs. con-
trol3371 ± 370, p = NS). From POE isozymes hydrolyzing cGMP in glomeruli,
POE-V activity (defined as cGMP-POE in the absence of Ca/CAM) was higher
in glomeruli from TIVCC (342 ± 72 vs. control: 154 ± 14, p <:: 0.05). while
POE-I activity (defined as total cGMP-POE minus POE-V) and total adenosine
3',5'-cyclic monophosphate (cAMP) POE activity were not significantly differ-
ent in glomerUli and IMCO from TIVCC and control dogs.
In order to test the physiological significance, zaprinast, a specific POE-V
inhibitor was infused intrarenally (5 JLg!kg!min) in TIVCC dogs (n = 6) and
compared to vehicle, ANP (100 ng!kg/min Lv.) in combination with zaprinast
showed a significantly higher urinary sodium excretion (104 ± 34 vs. ANP
alone: 69 ± 26 JLEq/min, p < 0.05) in association with increases in glomerular
filtratIOn rate (43 ± 7 vs. 31 ± 4 mllmin, p < 0.05).
. We conclude that cGMP-POE activity is upregulated in glomeruli in exper-
Imental heart failure. This increased activity in a known target site of ANP
action may represent a cellular mechanism of ANP resistance in heart fail-
ure by inactivating cGMP produced in response to ANP. Targeted pharmaco-
logical intervention via phosphodiesterase inhibition may improve the ANP
response in heart failure in vivo.
*p < 0.05 vS CONTROL. +p < 0.05 vs DCM
In the next set of experiments, Na+ ,K+-ATPase binding density (Bmax).
affinity (Kd), and ATPase actiVity (ACT) were computed from sarcolemmal
preparations. AT1 AT-II receptor blockade normalized Na+ ,K+-ATPase density
and Increased hydrolytic capacity. HR MAP PAP PCWP CI
Before Placebo 72 ± 9 Bl ± 8 36 ± 8 23 ± 5 2.3 ± 0.3
Peak Placebo 83 ± 12 75 ± 7 35 ± 8 21 ±6 23 ± 0,3
Before BNP 72± 11 85 ± 10 38± 7 25 ± 5 2.1 ± 0.3
Peak BNP 88± 20 68 ± 9* 22 ± 7* 10 ± 5* 2,7 ± 0.5t
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Hemodynamic Effects of Synthetic Human Brain
Natriuretic Peptide Infusion in Patients with Severe
Congestive Heart Failure: A Placebo-controlled,
Crossover Trial
Lee S. Marcus, Douglas Hart, Milton Packer, Madeline Yushak, Norma Medina,
Stuart D. Katz. Columbia University Col/ege of Physicians and Surgeons, New York, NY
Brain natriuretic peptide IBNP) and atrial natriuretic peptide (ANP) are
naturally-occurring peptide hormones with vasodilating and natriuretic prop-
erties, Although the two peptides are structurally similar, the primary site of
synthesis" receptor binding properties and metabolic clearance pathways of
BNP are distinct from those of AN P. While the plasma concentrations of both
BNP and ANP are increased in patients with congestive heart failure (CHF),
the biologic significance of this increase is uncertain since the vasodilatory
effects of exogenous ANP are attenuated in patients with CHF. To determine
if the vasodilating effects of BNP are similarly attenuated in patients with
CHF, the acute hemodynamic effects of exogenous synthetic human BNP in-
fusion (Scios Nova) were determined in 10 patients with chronic NYHA Class
III congestive heart failure (mean age 55 yrs, mean LVEF 21 %) in a double-
blind, placebo-controlled crossover trial. BNP or matching placebo solutions
were administered intravenously in 4 incremental doses ranging 0.003-0.1
JLg!kgfmin over 6 hours on two consecutive days. Heart rate (HRl. mean arte-
rial pressure (MAPl. mean pulmonary artery pressure (PAP). pulmonary cap-
illary wedge pressure (PCWP) and cardiac index (CI) were measured before
study drug administration on each day and 60 and 90 minutes after each
upward dose increment. Hemodynamic measurements before drug admin-
istration and peak hemodynamic responses to administration of human BNP
and placebo were as follows:
MYOVEL
57 ± 1
36± 1*
41 ± 1*
ACT (JLg!mglhr)
056 ± 009
0.37 ± 009*
0.96 ± 0.23*+
AP090
226 ± 8
257 ± 9*
183± 14*+
Kd (nM)
25.3 ± 15
19.9 ± 1.8*
22.7 ± 2.8
-78 ± 1 15B ± 9
-71 ± 1* 121 ± 5*
-76 ± 1+ 165 ± 13+
RMP VmaxLVEDV
69 ± 4
101 ± 7*
93 ± 6*
Bmax (pmol/mg)
3.2 ± 0.3
1.9 ± 0.3*
2.7 ± 0.2+
LVEF
73 ± 2
35 ± 3*
35 ± 2*
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Chronic Angiotensin II Receptor Blockade (AT1 AT-II)
Affects Myocyte Sarcolemmal Function and
Electrophysiology in Dilated Cardiomyopathy
Francis G. Spinale. R. Barry Hird, Rupak Mukherjee, Jennifer D. Walker, Henry
H. Holzgrefe, Michael J. Child, William H. Koster. Med Univ of South Carolina Chas
SC: Bristol Myers Squibb Research !nsMute, Princeton, NJ ' ,
CONTROL
OCM
OCM!AT-BLOCK
We tested the hypothesis that AT, AT-II receptor activation with the pro-
gression of dilated cardiomyopathy (OCMI causes fundamental changes
In myocyte (MYO) sarcolemmal processes. Six dogs were assigned to
each of 3 groups: (1) DCM: tachycardia induced OCM (pace 216;4
wks). (2) DCM/AT-BLOCK; chronic pace and concomitant treatment with
a specific non-peptide ATl AT-II antagonist (BMS 186295; 30 mg/kg
BIOI (3) CONTROL. LV ejection fraction (LVEFOfoI and end-diastolic volume
(LVEOV;cc) were measured by echo/cath. Simultaneous indices of MYO
membrane potential (resting;RMP;mV, upstroke velocity;Vmax;V/s, time
to 90% repolarization;AP090 ;ms) and contraction (velocity of shortening;
MYOVEL;JLm!sl were measured by videomicroscopy and microelectrodes.
CONTROL
OCM
OCM/AT-BLOCK
Summary: Concomitant AT, AT-II receptor blockade during the develop-
ment of OCM normalized MYO membrane potentials. A fundamental mech-
anism for these effects were preserved sarcolemmal Na+ ,K+ -ATPase density
and enhanced activity.
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1757-41 Differential Regulation of Renal Cyclic Nucleotide
Phosphodiesterases in Experimental Heart Failure
Roland R. Brandt, Holger Heinrich, Claudia C.S. Chini, Lawrence L. Aarhus,
Thomas P. Dousa, John C. Burnett, Jr.. Mayo Clinic and Foundation, Rochester, MN
Thoracic inferior vena caval constriction (TIVCC) is a model of experimen-
tallow cardiac output heart failure (HF) that results in sodium retention and
a blunted natriuretic response to atrial natriuretic peptide (ANP). Recogniz-
Ing that the biological actions of ANP are mediated through guanosine-3',5'-
cyclic monophosphate (cGMP) which is metabolized by multiple isozymes of
* indicates p < 0.01 versus peak placebo; t indicates p = 0.055 versus peak placebo
Two patients did not tolerate the highest dose of BNP because of transient
symptomatic hypotension. In conclusion, short-term intravenous infusion of
human BNP acutely improves hemodynamic function in patients with ad-
vanced CHF. These findings contrast with previous studies demonstrating
attenuated acute hemodynamic effects of exogenous ANP and suggest that
the physiologic and pharmacologic roles of these two natriuretic peptide
hormones may differ.
